Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.